Literature DB >> 11207279

Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions.

D K Bishop1, S Chan Wood, E J Eichwald, C G Orosz.   

Abstract

Both wild-type (WT) and IFN-gamma-deficient (IFN-gamma(-/-)) C57BL/6 mice can rapidly reject BALB/c cardiac allografts. When depleted of CD8(+) cells, both WT and IFN-gamma(-/-) mice rejected their allografts, indicating that these mice share a common CD4-mediated, CD8-independent mechanism of rejection. However, when depleted of CD4(+) cells, WT mice accepted their allografts, while IFN-gamma(-/-) recipients rapidly rejected them. Hence, IFN-gamma(-/-), but not WT mice developed an unusual CD8-mediated, CD4-independent, mechanism of allograft rejection. Allograft rejection in IFN-gamma(-/-) mice was associated with intragraft accumulation of IL-4-producing cells, polymorphonuclear leukocytes, and eosinophils. Furthermore, this form of rejection was resistant to treatment with anti-CD40 ligand (CD40L) mAb, which markedly prolonged graft survival in WT mice. T cell depletion studies verified that anti-CD40L treatment failed to prevent CD8-mediated allograft rejection in IFN-gamma(-/-) mice. However, anti-CD40L treatment did prevent CD4-mediated rejection in IFN-gamma(-/-) mice, although grafts were eventually rejected when CD8(+) T cells repopulated the periphery. The IL-4 production and eosinophil influx into the graft that occurred during CD8-mediated rejection were apparently epiphenomenal, since treatment with anti-IL-4 mAb blocked intragraft accumulation of eosinophils, but did not interfere with allograft rejection. These studies demonstrate that a novel, CD8-mediated mechanism of allograft rejection, which is resistant to experimental immunosuppression, can develop when IFN-gamma is limiting. An understanding of this mechanism is confounded by its association with Th2-like immune events, which contribute unique histopathologic features to the graft but are apparently unnecessary for the process of allograft rejection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207279     DOI: 10.4049/jimmunol.166.5.3248

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Unusual apoptosis in experimental cardiac rejection.

Authors:  Jiri T Beranek
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of interferon-gamma.

Authors:  Masayoshi Miura; Tarek El-Sawy; Robert L Fairchild
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

3.  Sequential evolution of IL-17 responses in the early period of allograft rejection.

Authors:  Sang Il Min; Jongwon Ha; Chung-Gyu Park; Jae Kyung Won; Yang Jin Park; Seung-Kee Min; Sang Joon Kim
Journal:  Exp Mol Med       Date:  2009-10-31       Impact factor: 8.718

4.  The classical complement pathway in transplantation: unanticipated protective effects of C1q and role in inductive antibody therapy.

Authors:  K Csencsits; B E Burrell; G Lu; E J Eichwald; G L Stahl; D K Bishop
Journal:  Am J Transplant       Date:  2008-06-28       Impact factor: 8.086

5.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

Review 6.  Programmed T cell differentiation: Implications for transplantation.

Authors:  Rebecca L Crepeau; Mandy L Ford
Journal:  Cell Immunol       Date:  2020-03-29       Impact factor: 4.868

7.  Cytotoxic effector function of CD4-independent, CD8(+) T cells is mediated by TNF-α/TNFR.

Authors:  Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Thomas A Pham; Samiya L Saklayen; Ginny L Bumgardner
Journal:  Transplantation       Date:  2012-12-15       Impact factor: 4.939

8.  Inhibition of recall responses through complementary therapies targeting CD8+ T-cell- and alloantibody-dependent allocytotoxicity in sensitized transplant recipients.

Authors:  Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Kartika Jayashankar; Sierra F Garcia; Mahmoud Abdel-Rasoul; Nico van Rooijen; Ginny L Bumgardner
Journal:  Cell Transplant       Date:  2012-10-11       Impact factor: 4.064

9.  Transplant acceptance following anti-CD4 versus anti-CD40L therapy: evidence for differential maintenance of graft-reactive T cells.

Authors:  S C Wood; G Lu; B E Burrell; D K Bishop
Journal:  Am J Transplant       Date:  2008-10       Impact factor: 8.086

10.  Regulation of alloimmune Th1 responses by the cyclin-dependent kinase inhibitor p21 following transplantation.

Authors:  Theodore H Welling; Guanyi Lu; Keri Csencsits; Sherri C Wood; Lamis Jarvinen; D Keith Bishop
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.